Dose-ramping design
Showing 1 - 25 of >10,000
Healthcare Resources in Chronic Lymphocytic Leukemia Initiating
Completed
- Chronic Lymphocytic Leukemia
-
Calgary, Alberta, Canada
- +12 more
Jul 7, 2022
Quality of Life, Health, Subjective Trial in Gig Harbor (RS blend, Placebo)
Completed
- Quality of Life
- Health, Subjective
- RS blend
- Placebo
-
Gig Harbor, WashingtonPersonalized Lifestyle Medicine Center
Apr 4, 2022
Heat Stress, Heat Exposure, Temperature Change, Body Trial in Ottawa (Humidity-ramp protocol, Above-inflection fixed-condition
Recruiting
- Heat Stress
- +3 more
- Humidity-ramp protocol
- +3 more
-
Ottawa, Ontario, CanadaUniversity of Ottawa
Jul 21, 2023
Ependymoma Trial in Memphis, Toronto (radiation, procedure, drug, device)
Active, not recruiting
- Ependymoma
- Irradiation
- +5 more
-
Memphis, Tennessee
- +1 more
Oct 28, 2022
MDD Trial in Montpellier, Saint Gély du Fesc (behavioral, biological, diagnostic test)
Recruiting
- Major Depressive Disorder
- Painful stimulations of major depressive patients
- +3 more
-
Montpellier, Occitanie, France
- +1 more
Dec 16, 2021
Tuberculosis, Pulmonary Trial (Optimised dose rifampicin, Standard dose rifampicin)
Not yet recruiting
- Tuberculosis, Pulmonary
- Optimised dose rifampicin
- Standard dose rifampicin
- (no location specified)
Sep 26, 2023
Leukemia, Myeloid, Acute Trial in Guangzhou, Hangzhou (BG1805)
Not yet recruiting
- Leukemia, Myeloid, Acute
- BG1805
-
Guangzhou, Guangdong, China
- +2 more
Nov 1, 2023
Transthyroxin Amyloidosis Cardiomyopathy Trial in Hangzhou (YOLT-201)
Recruiting
- Transthyroxin Amyloidosis Cardiomyopathy
-
Hangzhou, Zhejiang, Chinathe First Affiliated Hospital, Zhejiang University School of Med
Oct 7, 2023
B-cell Acute Lymphoblastic Leukemia (B-ALL) Trial in Worldwide (AZD0486)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
-
Duarte, California
- +30 more
Nov 13, 2023
Non Hodgkin Lymphoma Trial (TMhuCART19-IL18)
Not yet recruiting
- Non Hodgkin Lymphoma
- TMhuCART19-IL18
- (no location specified)
Aug 2, 2023
Severe Hemophilia A Without Inhibitor, Joint Bleed Trial in Bangkok ("Emicizumab", "HEMLIBRA®")
Recruiting
- Severe Hemophilia A Without Inhibitor
- Joint Bleed
- "Emicizumab", "HEMLIBRA®"
-
Bangkok, ThailandKing Chulalongkorn Memorial hospital
Nov 25, 2023
Poliomyelitis Trial in Geelong, Melbourne (Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio), Inactivated
Not yet recruiting
- Poliomyelitis
- Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)
- +3 more
-
Geelong, Victoria, Australia
- +1 more
Oct 30, 2023
Rheumatoid Arthritis Trial in Beijing (LNK01001 Dose A, LNK01001 Dose B, )
Completed
- Rheumatoid Arthritis
- LNK01001 Dose A
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
Oct 24, 2023
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)
Not yet recruiting
- Triple Negative Breast Cancer
- +13 more
- (no location specified)
Aug 29, 2023
![](/image/sponsor/irccs_national_neurological_institute_"c_mondino"_foundation)
Parkinson Disease, Pisa Syndrome Trial in Pavia (t-DCS group, Sham group)
Completed
- Parkinson Disease
- Pisa Syndrome
- t-DCS group
- Sham group
-
Pavia, ItalyNeurorehabilitation Department
Nov 11, 2020
Obstructive Sleep Apnea Trial (IHL-42X Low Dose, IHL-42X High Dose, Placebo)
Not yet recruiting
- Obstructive Sleep Apnea
- IHL-42X Low Dose
- +5 more
- (no location specified)
Nov 22, 2023
Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal
Not yet recruiting
- Esophagus Cancer
- +4 more
- Intravenous injection of P-IL-2
- P-IL-2 plus Anti-PD-1 Monoclonal Antibody
- (no location specified)
Apr 24, 2023
Ankylosing Spondylitis Trial in Beijing (LNK01001 Dose A, LNK01001 Dose B, Placebo)
Completed
- Ankylosing Spondylitis
- LNK01001 Dose A
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
Oct 10, 2023
